Innovative Connective Tissue Disease Screen

Phadia has launched an innovative new antinuclear antibody (ANA) screen for identification of connective tissue diseases (CTDs). The EliA ANA CTD Screen provides reliable and unambiguous detection of a wide range of

CTDs, offering superior specificity and sensitivity to HEp-2 based assays, even in difficult cases. It is designed to meet the needs of routine diagnostic testing, and is fully compatible with the ImmunoCAP automated laboratory systems for straightforward integration into laboratory workflows.

The screen uses a unique combination of concentrated and highly specific recombinant antigens to offer excellent sensitivity, with fewer false positives, and exceptional intra- and inter-laboratory reproducibility, ensuring simple data interpretation. In addition, the EliA ANA CTD Screen can be used alongside HEp-2 cellular techniques to provide valuable supplementary information in complex cases. By combining virtually all the relevant ANAs for CTDs in a single test, the screen provides clinicians with unambiguous and diagnostically relevant information, reducing

requirements for follow-up testing and improving patient outcomes.